CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project focuses on combating antimicrobial resistance by developing a combination of the antibiotic meropenem and a proprietary inhibitor, ANT3310. The aim is to effectively treat hospital-acquired infections caused by multidrug-resistant bacteria.
Antimicrobial resistance (AMR) due to multidrug-resistant Gram-negative bacteria are an increasingly serious healthcare threat, exacerbated by major economic issues underlying the development of new antibacterial drugs.
The effectiveness of β-lactam antibiotics, the most important class of antibacterial agents, is impaired by the production of β-lactamase enzymes by drug-resistant bacteria.
We are developing a combination of a well-known antibiotic (meropenem) and ANT3310, our proprietary, best-…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
